4/A: Sana Biotechnology Director Richard Mulligan Corrects Stock Option Acquisition in Amended SEC Filing

Richard Mulligan, a director at Sana Biotechnology, files an amended SEC Form 4 to correct the number of stock options acquired.

Summary

• Richard Mulligan, a director of Sana Biotechnology, Inc., filed an amended Form 4 with the SEC on July 15, 2024.
• The amendment corrects a clerical error regarding the number of stock option shares acquired on June 6, 2024.
• The corrected filing shows Mulligan acquired 65,000 stock options with an exercise price of $7.36.
• These options vest and become exercisable on the earlier of June 6, 2025, or immediately prior to the 2025 annual meeting of Sana's stockholders, contingent upon continuous service to Sana through that date.
• Following the transaction, Mulligan directly owns 65,000 derivative securities.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing correcting a clerical error, so it has a neutral sentiment.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in the biotechnology industry.

Key Dates